Duncan Bucknell

Duncan's presentation at Medical Devices Law and Policy Conference in Sydney, Australia

Shamnad Basheer, Duncan Bucknell and Nicholas Gruen discuss Pharmaceutical patent extensions, TRIPS, Free Trade Agreements and Pharmaceutical Manufacture for Export.

While blockbuster molecules have driven the growth of the Pharmaceutical Industry, the last decade has been a rough path for Innovator Pharmaceutical Companies due to low success rates in developing new...

There’s been a fair bit of fuss earlier today over Australia’s patent laws and allowing Australian manufacturers to manufacture for export only without infringing an existing patent. The Australian Financial Review...

Jeremy Phillips, Peter Ollier, Don Zuhn, Ben Lehman and Duncan Bucknell discuss Tom Tom and Microsoft case, Open source, Linux and the press, recent patent reform proposals in Australia and...

Our India team member and pharma & biotech IP Strategy specialist, Vandana Mamidanna will be speakng at a couple of upcoming events in Bombay / Mumbai. The first is a workshop...

Jeremy Phillips, Joff Wild, Jose Carlos Vaz e Dias and Duncan Bucknell discuss the recent decision of the Superior Court of Justice of Brazil which moved the date of effect of...

Jeremy Phillips, Shamnad Basheer, Nick Redfearn, Don Zuhn and Duncan Bucknell discuss Dr Reddy's, CIPLA, India, Brazil and goods seizures in Europe; Deferred patent examination; China vs USA

The Hatch Waxman legislation is intended to strike a balance between encouraging innovation and affordable access to medication. In short, the Act offers a patent term restoration to compensate the innovator...

Jeremy Phillips, Peter Ollier and Duncan Bucknell discuss Reverse payments in US Pharma, Vintage prior art, The ever growing prior art base and Utility models